Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of Zevalin in follicular non-Hodgkin B-cell lymphomas
2006-004850-26Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- May 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall survival. Started May 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2006-004850-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004850-26.